<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03057015</url>
  </required_header>
  <id_info>
    <org_study_id>CHRMS 17-0107</org_study_id>
    <nct_id>NCT03057015</nct_id>
  </id_info>
  <brief_title>Addition of Clonidine to Ropivacaine in Adductor Canal Block</brief_title>
  <official_title>Addition of Clonidine to Ropivacaine in Adductor Canal Block for Postoperative Pain Relief in Total Knee Arthroplasty: A Prospective Randomized Double Blind Placebo Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Vermont</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Vermont</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Total knee arthroplasty (knee replacement) is a common orthopedic procedure for&#xD;
      osteoarthritis. This procedure is performed either under general anesthesia or spinal&#xD;
      anesthesia; after the procedure in the recovery room, these patients undergo adductor canal&#xD;
      block, which is a nerve block to provide 8-14 hours of postoperative pain control. For this&#xD;
      nerve block, 15-20 ml of local anesthetic is combined with adjuvant medications to improve&#xD;
      the quality of pain control as well as the duration of pain relief. The primary local&#xD;
      anesthetic used for adductor canal block is ropivacaine, and the commonly used adjuvants are&#xD;
      epinephrine and dexamethasone.&#xD;
&#xD;
      There is conflicting data available in the literature regarding efficacy of addition of&#xD;
      clonidine to the local anesthetic injection in peripheral nerve blocks, and there is no data&#xD;
      assessing the efficacy of this medication in adductor canal blocks.&#xD;
&#xD;
      Once the consent process is completed, patients are enrolled in two arms. Upon conclusion of&#xD;
      surgery, a sealed and coded envelope with either clonidine or the placebo syringe will be&#xD;
      given to the acute pain service staff performing the nerve block. This will be mixed with&#xD;
      local anesthetic solution and injected in the adductor canal under ultrasound guidance.&#xD;
&#xD;
      The primary outcome measure will be the duration of analgesia, which will be assessed as the&#xD;
      time interval between placement of adductor canal block to the first request of opioid&#xD;
      analgesic by patients (which will be obtained from hospital electronic medical records).&#xD;
      Secondary outcomes will include:&#xD;
&#xD;
        1. Duration of sensory block, which will be assessed as the time interval between injection&#xD;
           of local anesthetic and report of postoperative pain of 3 or more on an 11 point scale&#xD;
           (0=no pain; 10= worst pain imaginable) by the patient (this will be assessed every 4&#xD;
           hours).&#xD;
&#xD;
        2. Duration of motor block, which will be assessed as the time interval between the onset&#xD;
           of motor block to complete recovery of motor block by assessing straight leg raise&#xD;
           strength (this will be assessed every 4 hours).&#xD;
&#xD;
        3. Cumulative 24 and 48 hour opioid analgesic use.&#xD;
&#xD;
        4. Post-block pain scores, evaluated by an 11 point pain score (0-10), which will be done&#xD;
           every 15 minutes for the first hour after surgery and every 4 hours thereafter for 24&#xD;
           hours.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">May 22, 2017</start_date>
  <completion_date type="Anticipated">February 28, 2019</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of Analgesia</measure>
    <time_frame>24 hours for primary outcome</time_frame>
    <description>the time interval between placement of adductor canal block to the first request of opioid analgesic by patients</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Postoperative Pain</condition>
  <arm_group>
    <arm_group_label>Clonidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 mcg clonidine + 0.5% ropivacaine + 2 mg dexamethasone + 5 mcg/ml epinephrine in 20 ml solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0.5 ml normal saline + 0.5% ropivacaine + 2 mg dexamethasone + 5 mcg/ml epinephrine in 20 ml solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clonidine</intervention_name>
    <description>50 mcg Clonidine added to the solution of 0.5% ropivacaine, 2 mg dexamethasone and 5 mcg/ml epinephrine for adductor canal block-present in the treatment group.</description>
    <arm_group_label>Clonidine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Normal saline added to the solution of 0.5% ropivacaine, 2 mg dexamethasone and 5 mcg/ml epinephrine for adductor canal block-present in the placebo group.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine</intervention_name>
    <description>Clonidine or Placebo added to the solution of 0.5% ropivacaine, 2 mg dexamethasone and 5 mcg/ml epinephrine for adductor canal block-present in both treatment and placebo groups.</description>
    <arm_group_label>Clonidine</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Clonidine or Placebo added to the solution of 0.5% ropivacaine, 2 mg dexamethasone and 5 mcg/ml epinephrine for adductor canal block-present in both treatment and placebo groups.</description>
    <arm_group_label>Clonidine</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epinephrine</intervention_name>
    <description>Clonidine or Placebo added to the solution of 0.5% ropivacaine, 2 mg dexamethasone and 5 mcg/ml epinephrine for adductor canal block-present in both treatment and placebo groups.</description>
    <arm_group_label>Clonidine</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men and women ages 18 and older&#xD;
&#xD;
          -  ASA physical status classification system I, II and III (healthy patient or patient&#xD;
             with mild to moderate systemic disease)&#xD;
&#xD;
          -  Patient coming in for elective total knee arthroplasty under general or neuraxial&#xD;
             anesthesia and postoperative adductor canal block&#xD;
&#xD;
          -  Patients staying for at least 24 hrs post operatively&#xD;
&#xD;
          -  Patients who provide informed consent&#xD;
&#xD;
          -  Patients presenting for surgery &gt;1 hour in length and &lt;6 hours.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of recent common colds, upper respiratory infections or immune deficiencies&#xD;
&#xD;
          -  Patients allergic to clonidine&#xD;
&#xD;
          -  Pregnant women (all women of childbearing age undergo pregnancy testing prior to&#xD;
             anesthesia as per UVMMC peri-operative protocol)&#xD;
&#xD;
          -  Patients who are already on chronic clonidine therapy for management of blood pressure&#xD;
&#xD;
          -  Patients on chronic opioid therapy defined as more than 10 mg of oxycodone per day (or&#xD;
             equivalent doses of other opioid analgesics)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Borzoo Farhang, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Vermont Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Borzoo Farhang, DO</last_name>
    <phone>8028819927</phone>
    <email>borzoo.farhang@uvmhealth.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Vermont Medical Center</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Borzoo Farhang, DO</last_name>
      <phone>802-881-9927</phone>
      <email>borzoo.farhang@uvmhealth.org</email>
    </contact>
    <investigator>
      <last_name>Borzoo Farhang, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>February 13, 2017</study_first_submitted>
  <study_first_submitted_qc>February 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 17, 2017</study_first_posted>
  <last_update_submitted>May 2, 2018</last_update_submitted>
  <last_update_submitted_qc>May 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Vermont</investigator_affiliation>
    <investigator_full_name>Borzoo Farhang</investigator_full_name>
    <investigator_title>Clinical Instructor of Anesthesiology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Clonidine</mesh_term>
    <mesh_term>Epinephrine</mesh_term>
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

